CN105687204A - 一种甘氨酸金属螯合物复合物及其制备方法 - Google Patents
一种甘氨酸金属螯合物复合物及其制备方法 Download PDFInfo
- Publication number
- CN105687204A CN105687204A CN201610238160.9A CN201610238160A CN105687204A CN 105687204 A CN105687204 A CN 105687204A CN 201610238160 A CN201610238160 A CN 201610238160A CN 105687204 A CN105687204 A CN 105687204A
- Authority
- CN
- China
- Prior art keywords
- glycine
- glycinate
- metal chelate
- chelate complex
- adjuvant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 title claims abstract description 231
- 239000004471 Glycine Substances 0.000 title claims abstract description 117
- 229910052751 metal Inorganic materials 0.000 title claims abstract description 59
- 239000002184 metal Substances 0.000 title claims abstract description 58
- 150000004697 chelate complex Chemical class 0.000 title claims abstract description 54
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000011575 calcium Substances 0.000 claims abstract description 29
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 27
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 26
- VVYPIVJZLVJPGU-UHFFFAOYSA-L copper;2-aminoacetate Chemical compound [Cu+2].NCC([O-])=O.NCC([O-])=O VVYPIVJZLVJPGU-UHFFFAOYSA-L 0.000 claims abstract description 19
- 229940004916 magnesium glycinate Drugs 0.000 claims abstract description 15
- AACACXATQSKRQG-UHFFFAOYSA-L magnesium;2-aminoacetate Chemical compound [Mg+2].NCC([O-])=O.NCC([O-])=O AACACXATQSKRQG-UHFFFAOYSA-L 0.000 claims abstract description 15
- 229940071566 zinc glycinate Drugs 0.000 claims abstract description 15
- UOXSXMSTSYWNMH-UHFFFAOYSA-L zinc;2-aminoacetate Chemical compound [Zn+2].NCC([O-])=O.NCC([O-])=O UOXSXMSTSYWNMH-UHFFFAOYSA-L 0.000 claims abstract description 15
- 239000013522 chelant Substances 0.000 claims description 34
- 239000002671 adjuvant Substances 0.000 claims description 28
- 235000013336 milk Nutrition 0.000 claims description 20
- 239000008267 milk Substances 0.000 claims description 20
- 210000004080 milk Anatomy 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 20
- 229940011405 cupric glycinate Drugs 0.000 claims description 18
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- 239000008187 granular material Substances 0.000 claims description 15
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 claims description 14
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 14
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 14
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 7
- 229930006000 Sucrose Natural products 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- 239000005720 sucrose Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 238000007908 dry granulation Methods 0.000 claims description 4
- 229960002449 glycine Drugs 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- -1 sieve Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 238000005550 wet granulation Methods 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 239000011573 trace mineral Substances 0.000 abstract description 38
- 235000013619 trace mineral Nutrition 0.000 abstract description 38
- 239000011701 zinc Substances 0.000 abstract description 15
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract description 14
- 229910052725 zinc Inorganic materials 0.000 abstract description 14
- 239000013589 supplement Substances 0.000 abstract description 12
- 239000010949 copper Substances 0.000 abstract description 8
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract description 7
- 229910052802 copper Inorganic materials 0.000 abstract description 7
- 239000011777 magnesium Substances 0.000 abstract description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract description 4
- 150000001413 amino acids Chemical class 0.000 abstract description 4
- 229910052749 magnesium Inorganic materials 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 4
- GIPOFCXYHMWROH-UHFFFAOYSA-L 2-aminoacetate;iron(2+) Chemical compound [Fe+2].NCC([O-])=O.NCC([O-])=O GIPOFCXYHMWROH-UHFFFAOYSA-L 0.000 abstract 2
- JNMKPXXKHWQWFB-UHFFFAOYSA-L 2-aminoacetate;manganese(2+) Chemical compound [Mn+2].NCC([O-])=O.NCC([O-])=O JNMKPXXKHWQWFB-UHFFFAOYSA-L 0.000 abstract 1
- OFNJDDJDXNMTHZ-UHFFFAOYSA-L calcium;2-aminoacetate Chemical compound [Ca+2].NCC([O-])=O.NCC([O-])=O OFNJDDJDXNMTHZ-UHFFFAOYSA-L 0.000 abstract 1
- 230000000536 complexating effect Effects 0.000 abstract 1
- 229910052742 iron Inorganic materials 0.000 abstract 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 description 14
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 13
- 229930195725 Mannitol Natural products 0.000 description 13
- 239000000594 mannitol Substances 0.000 description 13
- 235000010355 mannitol Nutrition 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 238000002156 mixing Methods 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000001476 alcoholic effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000470 constituent Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001502 supplementing effect Effects 0.000 description 4
- CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical compound NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 2
- 206010044278 Trace element deficiency Diseases 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 150000002333 glycines Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000020939 nutritional additive Nutrition 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- PBWPWIZUYLTJNF-UHFFFAOYSA-N 2-aminoacetic acid;calcium Chemical compound [Ca].NCC(O)=O PBWPWIZUYLTJNF-UHFFFAOYSA-N 0.000 description 1
- HGSXDBRNFBJIMX-UHFFFAOYSA-N 2-aminoacetic acid;zinc Chemical compound [Zn].NCC(O)=O HGSXDBRNFBJIMX-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 229910017518 Cu Zn Inorganic materials 0.000 description 1
- 229910017752 Cu-Zn Inorganic materials 0.000 description 1
- 229910017943 Cu—Zn Inorganic materials 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- WDVJLIUIBOEMLF-UHFFFAOYSA-N [Cu].[Zn].[Mn].[Fe].[Mg] Chemical compound [Cu].[Zn].[Mn].[Fe].[Mg] WDVJLIUIBOEMLF-UHFFFAOYSA-N 0.000 description 1
- PGTXKIZLOWULDJ-UHFFFAOYSA-N [Mg].[Zn] Chemical compound [Mg].[Zn] PGTXKIZLOWULDJ-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- OBODKGDXEIUEIH-DAWLFQHYSA-N all-trans-3-hydroxyretinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CC(O)CC1(C)C OBODKGDXEIUEIH-DAWLFQHYSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 208000010499 anthracosilicosis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- TVZPLCNGKSPOJA-UHFFFAOYSA-N copper zinc Chemical compound [Cu].[Zn] TVZPLCNGKSPOJA-UHFFFAOYSA-N 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- ALKZAGKDWUSJED-UHFFFAOYSA-N dinuclear copper ion Chemical compound [Cu].[Cu] ALKZAGKDWUSJED-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 150000002500 ions Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000008127 lead poisoning Diseases 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- RMDJVOZETBHEAR-LQYWTLTGSA-N vitamin D5 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CC[C@@H](CC)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C RMDJVOZETBHEAR-LQYWTLTGSA-N 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1522—Inorganic additives, e.g. minerals, trace elements; Chlorination or fluoridation of milk; Organic salts or complexes of metals other than natrium or kalium; Calcium enrichment of milk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
一种甘氨酸金属螯合物复合物,属于氨基酸微量元素络合的技术领域,包括辅料、两种或两种以上的甘氨酸金属螯合物,所述的金属螯合物包括甘氨酸钙、甘氨酸镁、甘氨酸锌、甘氨酸亚铁、甘氨酸铁、甘氨酸铜、甘氨酸锰。还公开了上述甘氨酸金属螯合物复合物的制备方法,制备的金属螯合物混合物可以达到均衡补充微量元素的目的,用来满足人体对钙镁锌铁铜锰等元素的需求,制备方法简单易操作。
Description
技术领域
本发明属于氨基酸微量元素络合的技术领域,涉及甘氨酸金属螯合物,具体涉及一种甘氨酸金属螯合物复合物及其制备方法,制备的甘氨酸金属螯合物复合物可以达到均衡补充微量元素的目的,用来满足人体对钙镁锌铁铜锰等元素的需求,避免当同时需要补充多种微量元素时,因为补充量的不同,造成微量元素中毒的现象。
背景技术
微量元素与人类的健康息息相关,人体中微量元素存在协同和拮抗作用。锌能促进铁的吸收,有协同造血作用。研究表明,血清中铜、锌含量有一定的比值,正常为0.9-1.27,在很多疾病中,Cu-Zn比值发生变化,如冠心病、肿瘤、矽肺病等。实验证明锌还能抑制铅在肠道中的吸收,降低铅毒性,锌可竞争性置换铅的作用,从而预防铅中毒。铁:在缺铁性贫血患者细胞内,铜、锌浓度降低。而机体缺铜时不仅使铁的吸收量减少,而且铁的利用也发生困难,缺铁还影响锌的吸收。铜:铜参与造血过程,影响铁的吸收、运送和利用。铜能促进铁进入骨髓,加速血红蛋白合成,没有铜,铁就不能传递,且不能与血红素结合,形成缺铁性贫血。而锰适量时,可改善铜的利用和吸收。镁和钙相互作用,相互影响。动物试验发现,镁影响大鼠成骨细胞生长分泌,可促进成骨细胞碱性磷酸酶活性及蛋白质分泌,如果没有镁的参与无论补钙多少,仍会骨质疏松。因此在人体内钙和镁离子之间保持一定的比例关系很重要。
微量元素被认为是关系到人类健康和长寿的一个充满希望的新领域,已引起国内外营养界和医学界的普遍重视。为了预防人体内微量元素缺乏,常用的方法是以微量元素营养添加剂的形式进行补充。微量元素营养添加剂经历了无机盐、简单有机化合物和微量元素氨基酸螯合物三个发展阶段。与前面两者相比,微量元素氨基酸螯合物由于毒性小,生物利用率高,可作为饲料添加剂改善饲料应用效果,提高饲料报酬;可用于婴幼儿、孕产妇和老年人的保健食品,作为矿物质和蛋白质营养强化剂。随着研究的深入完善,还可用作医药制剂,用于钙、铁、锌等微量元素缺乏症的治疗。甘氨酸金属螯合物是微量元素氨基酸螯合物中的一种,由金属离子与甘氨酸分子形成的螯合物,具有环状结构。甘氨酸金属螯合物的结构如下:X可以是Ca(Ⅱ),Mg(Ⅱ),Zn(Ⅱ),Fe(Ⅲ),Fe(Ⅱ),Cu(Ⅱ),Mn(Ⅱ)。
甘氨酸金属螯合物的独特结构,使得它有比较稳定的化学性质,在体内pH值环境下,金属离子的生物学效价得到保护。甘氨酸金属螯合物的生理功能有:促进金属离子的吸收,生物学效价比较高;形成缓冲系统,增强机体内酶的活性,提高维生素利用率;调节机体免疫力等。
甘氨酸金属螯合物作为营养添加剂,目前的产品均是单一补充一种微量元素,如发明专利CN101531609和CN101225050等均为制备甘氨酸钙的专利,还有市场上有的甘氨酸钙片,甘氨酸锌片等产品。
发明内容
本发明主要解决的技术问题是克服单一补充一种微量元素的弊端,充分考虑不同微量元素之间的协同作用,使微量元素含量在人体内保持平衡,因此发明了一种甘氨酸金属螯合物复合物及其制备方法,由两种或两种以上的甘氨酸金属螯合物按不同比例配制而成,可以制成颗粒、片剂、胶囊、软胶囊。
本发明为实现其目的采用的技术方案是:
一种甘氨酸金属螯合物复合物,包括辅料、两种或两种以上的甘氨酸金属螯合物,所述的金属螯合物包括甘氨酸钙、甘氨酸镁、甘氨酸锌、甘氨酸亚铁、甘氨酸铁、甘氨酸铜、甘氨酸锰。
每单位制剂1000mg中,含有甘氨酸钙40-500mg,甘氨酸镁20-200mg,甘氨酸锌10-100mg,甘氨酸铁20-300mg,甘氨酸亚铁20-300mg,甘氨酸铜0.5-20mg,甘氨酸锰0.5-20mg。
每单位制剂1000mg的甘氨酸金属螯合物复合物包括:甘氨酸钙60-400mg,甘氨酸镁50-100mg,甘氨酸铁60-200mg,甘氨酸亚铁30-200mg,甘氨酸铜5-10mg。
每单位制剂1000mg的甘氨酸金属螯合物复合物包括:甘氨酸镁120-180mg,甘氨酸亚铁210-270mg,甘氨酸铜6-8mg,甘氨酸锰0.8-2mg。
每单位制剂1000mg的甘氨酸金属螯合物复合物包括:甘氨酸锌40-60mg,甘氨酸铁220-260mg,甘氨酸铜15-18mg。
所述的辅料为聚乙烯吡咯烷酮、硬脂酸镁、蔗糖、乳糖、淀粉、奶粉、维生素、水、醇中的一种或多种。
将甘氨酸金属螯合物与辅料经粉碎、过筛、混合、制粒,制粒时,采用干法制粒或湿法制粒,制得甘氨酸金属螯合物复合物。
制备的甘氨酸金属螯合物复合物为颗粒剂、片剂、胶囊剂。
本发明解决了现有技术中在补充微量元素时,只能补充一种,无法多种同时补充的问题;同时解决了如果同时缺几种微量元素时,想补充多种微量元素,只能通过服用多种微量元素来进行补充,服用麻烦,而且单独补充任何一种微量元素,吸收效果都非常差的问题!同时,避免因同时服用多种微量元素剂,例如同时服用甘氨酸螯合物钙片和甘氨酸螯合物锌,会造成微量元素间的相互影响和吸收、利用率问题,两者服用要间隔一段时间,以及在人体内分解后,对肠、胃、肝、肾的刺激损伤问题。
本发明的甘氨酸金属螯合物复合物可同时补充甘氨酸和金属元素钙、铁、亚铁、镁锌等微量元素,弥补了市场上现有产品补充单一元素的不足,并且因为这些元素为甘氨酸螯合物,有利于人体的吸收和利用,增强了补充效果。
本发明通过将多种甘氨酸螯合物与辅料进行混合,制备成了甘氨酸金属螯合物复合物,本甘氨酸金属螯合物复合物可同时补充多种微量元素,且吸收效果好,对人体无刺激,本甘氨酸金属螯合物复合物中各甘氨酸金属螯合物复合时,与相同的辅料进行复合,避免了单一微量元素剂因为各自的辅料不同,在同时补充的时候,造成对其他组分药效的分解,降低药效,同时也避免了辅料间及辅料与微量元素间的结合,而影响微量元素的吸收!此外,因为是相同的辅料,相较于现有的同时服用多种微量元素剂,本发明的吸收效果明显优于现有的同时服用多种微量元素剂,吸收效果提高了20-30%。实现相同的吸收效果,现有的同时服用多种微量元素剂需要服用甘氨酸螯合物A为0.8、甘氨酸螯合物B为0.8、甘氨酸螯合物C为0.5,而需要服用本发明甘氨酸金属螯合物复合物(包括甘氨酸螯合物A、甘氨酸螯合物B、甘氨酸螯合物C和辅料)为1.3,服用量减少了20-40%。
本发明甘氨酸金属螯合物复合物,具有良好的化学、生化稳定性,在体内pH条件下溶解性好,容易被吸收,生物利用率高,具有抗干扰、缓解矿物质之间的拮抗作用,具有补充氨基酸和多种微量元素的双重作用,本发明通过在混合时,各个甘氨酸螯合物与相同的辅料混合,降低了各甘氨酸螯合物间在体内的吸收拮抗作用,同时也防止在消化道内胃酸的作用下,分离出的离子形成不溶化合物,有利于微量元素的吸收,减少对摄入的维生素的破坏,降低氧化降解,减少微量元素的损失。
具体实施方式
现有产品多数为甘氨酸螯合钙,少量的甘氨酸螯合锌产品,而复合金属补充剂一次性解决了现在困扰人们的多种微量元素缺乏的问题,因此开发一种甘氨酸金属螯合物复合物有着很现实的意义。下面结合具体实施例对本发明作进一步的公开。
实施例1
1000g甘氨酸金属螯合物复合物:包括甘氨酸钙150g,甘氨酸镁45g,维生素D5g,奶粉280g,乳糖400g,甘露醇100g,95%PVP乙醇溶液适量。
实施例2
1000g甘氨酸金属螯合物复合物:甘氨酸钙200g,甘氨酸镁50g,维生素D6g,奶粉180g,乳糖424g,甘露醇100g,硬脂酸镁20g,95%PVP乙醇溶液适量。
实施例3
1000g甘氨酸金属螯合物复合物:甘氨酸亚铁100g,甘氨酸铜3g,甘氨酸锰1g,奶粉280g,乳糖496g,甘露醇100g,95%PVP乙醇溶液适量。
实施例4
1000g甘氨酸金属螯合物复合物:甘氨酸亚铁120g,甘氨酸铜4g,甘氨酸锌3g,奶粉280g,蔗糖473g,甘露醇100g,95%PVP乙醇溶液适量。
实施例5
1000g甘氨酸金属螯合物复合物:甘氨酸亚铁280g,甘氨酸钙90g,甘氨酸锌75g,奶粉100g,甘露醇105g,硬脂酸镁150g,95%PVP乙醇溶液200g。
实施例6
1000g甘氨酸金属螯合物复合物包括:甘氨酸锌50g,甘氨酸铁240g,甘氨酸铜16g,奶粉300g,蔗糖300g,甘露醇94g。
实施例7
1000g甘氨酸金属螯合物复合物包括:甘氨酸钙87.9g、甘氨酸铁350g、甘氨酸锌44.1g,奶粉120g、甘露醇230g、聚乙烯比咯烷酮168g。
实施例8
1000g甘氨酸金属螯合物复合物包括:甘氨酸锌210g、甘氨酸镁40g、甘氨酸铁180g、甘氨酸铜35g、淀粉230g、蔗糖230g、维生素E75g。
实施例9
1000g甘氨酸金属螯合物复合物包括:甘氨酸锌160g、甘氨酸铁210g、甘氨酸亚铁80g,硬脂酸镁500g、水35g、聚乙烯吡咯烷酮15g。
实施例10
1000g甘氨酸金属螯合物复合物包括:甘氨酸钙42g、甘氨酸锌29g、甘氨酸铜95g、甘氨酸锰80g、甘露醇280g、奶粉115g、硬脂酸镁320g、聚乙烯比咯烷酮39g。
实施例11
1000g甘氨酸金属螯合物复合物包括:甘氨酸钙100g,甘氨酸镁80g,甘氨酸锌30g,甘氨酸铁210g,甘氨酸亚铁40g,甘氨酸铜15g,甘氨酸锰15g,维生素A30g,维生素D80g,蔗糖140g,甘露醇60g,奶粉113g,硬脂酸镁87g。
上述甘氨酸金属螯合物复合物由下述方法制备,制备成片剂:
(一)粉碎、过筛:将上述甘氨酸螯合物与辅料先通过粉碎机进行粉碎,然后将粉碎后的物料通过60-80目筛,备用;
(二)混合:混合时采用过筛、振荡筛的方式混合;
(三)制粒:制粒采用干法制粒的方式;
(四)将硬脂酸镁与干颗粒的混合;
(五)压片:将混合颗粒置压片机调节片重,0.5g/片,压片,得片剂;
(六)包装、检验、入库:将片剂装入检验合格的瓶中,检验合格后方可入库。
实施例12
1000g甘氨酸金属螯合物复合物包括:甘氨酸钙180g,甘氨酸镁150g,甘氨酸铁60g,甘氨酸亚铁80g,甘氨酸铜5g,淀粉150g,聚乙烯比咯烷酮20g,甘露醇135g,奶粉220g。
上述甘氨酸金属螯合物复合物由下述方法制备,制备成颗粒剂:
(一)粉碎、过筛
将上述甘氨酸螯合物与辅料先通过粉碎机进行粉碎,然后将粉碎后的物料通过60-80目筛,备用;
(二)混合:混合时采用过筛、振荡筛的方式混合;
(三)制粒:制成片剂时,制粒采用湿法制粒的方式;
(四)制粒完成后进行干燥,得到颗粒剂。
实施例13
1000g甘氨酸金属螯合物复合物包括:甘氨酸镁80g,甘氨酸亚铁230g,甘氨酸铜7g,甘氨酸锰1g,维生素D3g、维生素E5g,奶粉300g,甘露醇80g,淀粉200g,蔗糖80g,95%PVP乙醇溶液14g。
上述甘氨酸金属螯合物复合物由下述方法制备,制备成胶囊剂:
(一)粉碎、过筛:将上述甘氨酸螯合物与辅料先通过粉碎机进行粉碎,然后将粉碎后的物料通过60-80目筛,备用;
(二)混合:混合时采用过筛、振荡筛的方式混合;
(三)制粒:制成片剂时,制粒采用干法制粒的方式;
(四)将制粒得到的颗粒装入到胶囊壳中,在经过除粉、胶囊封口、打光、包装的后处理工序,质检合格后,制成胶囊剂。
当钙元素与锌元素同时存在时,控制钙元素与锌元素的质量比为1:(0.25-1.5),同时控制辅料中奶粉的用量为甘氨酸螯合物复合物质量的10-12%,辅料优选甘露醇和聚乙烯比咯烷酮与奶粉混合,当钙元素与锌元素的质量比控制在这个比例范围内时,结合辅料奶粉的加入,可以化解两者的拮抗效果,不会因为与载体肽结合的影响,而造成吸收率低的现象。同时辅料奶粉的用量也至关重要,当辅料奶粉的用量小于10%时,因为与载体肽结合的原因,钙元素和锌元素的吸收都会受到影响,同时会影响甘氨酸螯合物复合物的稳定性;当辅料奶粉的用量大于12%时,钙元素和锌元素的吸收率提升不大,还会影响最后制剂的成型,而且,如果还存在其他微量元素,反而会影响其他微量元素的吸收。
本发明甘氨酸金属螯合物复合物既可用于对人体微量元素的补充,也可以用于饲料添加剂,本发明的辅料中,聚乙烯比咯烷酮具有优良的生物相容性,且不参与人体新陈代谢,有助于制剂的成型,提高甘氨酸金属螯合物复合物的稳定性,提高甘氨酸金属螯合物复合物在体内的溶解度和吸收率。甘露醇的加入,可以提高制剂的成型效果,提高甘氨酸金属螯合物复合物的稳定性,避免各氨基酸螯合物间的粘连而影响相互间的吸收。奶粉的加入除了用于成型制剂、提高口感外,还可以补充蛋白质、亚油酸、亚麻酸,避免微量元素因与载体肽结合的原因,影响微量元素的吸收。
Claims (8)
1.一种甘氨酸金属螯合物复合物,其特征在于:包括辅料、两种或两种以上的甘氨酸金属螯合物,所述的甘氨酸金属螯合物包括甘氨酸钙、甘氨酸镁、甘氨酸锌、甘氨酸亚铁、甘氨酸铁、甘氨酸铜、甘氨酸锰。
2.根据权利要求1所述的一种甘氨酸金属螯合物复合物,其特征在于:每单位制剂1000mg中,含甘氨酸钙40-500mg,甘氨酸镁20-200mg,甘氨酸锌10-100mg,甘氨酸铁20-300mg,甘氨酸亚铁20-300mg,甘氨酸铜0.5-20mg,甘氨酸锰0.5-20mg,余量为辅料。
3.根据权利要求1所述的一种甘氨酸金属螯合物复合物,其特征在于,每单位制剂1000mg的甘氨酸金属螯合物复合物含甘氨酸钙60-400mg,甘氨酸镁50-100mg,甘氨酸铁60-200mg,甘氨酸亚铁30-200mg,甘氨酸铜5-10mg,余量为辅料。
4.根据权利要求1所述的一种甘氨酸金属螯合物复合物,其特征在于:每单位制剂1000mg的甘氨酸金属螯合物复合物含甘氨酸镁120-180mg,甘氨酸亚铁210-270mg,甘氨酸铜6-8mg,甘氨酸锰0.8-2mg,余量为辅料。
5.根据权利要求1所述的一种甘氨酸金属螯合物复合物,其特征在于:每单位制剂1000mg的甘氨酸金属螯合物复合物含甘氨酸锌40-60mg,甘氨酸铁220-260mg,甘氨酸铜15-18mg,余量为辅料。
6.根据权利要求1所述的一种甘氨酸金属螯合物复合物,其特征在于:所述的辅料为聚乙烯吡咯烷酮、硬脂酸镁、蔗糖、乳糖、淀粉、奶粉、维生素、水、醇中的一种或多种。
7.一种制备如权利要求1所述的甘氨酸金属螯合物复合物的方法,其特征在于:将甘氨酸金属螯合物与辅料经粉碎、过筛、混合、制粒,制得甘氨酸金属螯合物复合物,制粒时,采用干法制粒或湿法制粒。
8.根据权利要求7所述的制备甘氨酸金属螯合物复合物的方法,其特征在于:制备的甘氨酸金属螯合物复合物为颗粒剂、片剂或胶囊剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610238160.9A CN105687204B (zh) | 2016-04-15 | 2016-04-15 | 一种甘氨酸金属螯合物复合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610238160.9A CN105687204B (zh) | 2016-04-15 | 2016-04-15 | 一种甘氨酸金属螯合物复合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105687204A true CN105687204A (zh) | 2016-06-22 |
CN105687204B CN105687204B (zh) | 2018-05-25 |
Family
ID=56217067
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610238160.9A Active CN105687204B (zh) | 2016-04-15 | 2016-04-15 | 一种甘氨酸金属螯合物复合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105687204B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109010364A (zh) * | 2018-09-12 | 2018-12-18 | 仲恺农业工程学院 | 一种包衣结构的甘氨酸亚铁肠溶型缓释微丸及制备方法 |
CN109043221A (zh) * | 2018-09-25 | 2018-12-21 | 建德市维丰饲料有限公司 | 一种用于家禽的饲料预混料的制备方法及其产品和应用 |
CN112675160A (zh) * | 2020-12-31 | 2021-04-20 | 河北力维素科技有限公司 | 一种氨基酸矿物盐微量元素组合物及其制备方法 |
CN113317428A (zh) * | 2021-06-16 | 2021-08-31 | 海而思(郑州)科技有限公司 | 一种钙铁锌固体制剂及其制备方法 |
RU2817424C1 (ru) * | 2023-08-23 | 2024-04-16 | Федеральное Государственное бюджетное научное учреждение "Федеральный научный центр биологических систем и агротехнологий российской академии наук" | Способ повышения содержания макро- и эссенциальных элементов в мясе бройлеров |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1333020A (zh) * | 2000-06-16 | 2002-01-30 | 马赛厄斯·拉思 | 生化物质作为组合物用于预防和治疗因人体器官中平滑肌细胞收缩而引起的影响健康的疾病 |
CN102335266A (zh) * | 2011-10-22 | 2012-02-01 | 苏洋 | 一种补钙的保健品 |
CN103690599A (zh) * | 2013-12-03 | 2014-04-02 | 青岛海芬海洋生物科技有限公司 | 一种含海洋生物成分的口腔溃疡用软膏 |
US20140127351A1 (en) * | 2012-11-02 | 2014-05-08 | Robert DiSilvestro | Nutritional supplements including meal replacements and related methods |
-
2016
- 2016-04-15 CN CN201610238160.9A patent/CN105687204B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1333020A (zh) * | 2000-06-16 | 2002-01-30 | 马赛厄斯·拉思 | 生化物质作为组合物用于预防和治疗因人体器官中平滑肌细胞收缩而引起的影响健康的疾病 |
CN102335266A (zh) * | 2011-10-22 | 2012-02-01 | 苏洋 | 一种补钙的保健品 |
US20140127351A1 (en) * | 2012-11-02 | 2014-05-08 | Robert DiSilvestro | Nutritional supplements including meal replacements and related methods |
CN103690599A (zh) * | 2013-12-03 | 2014-04-02 | 青岛海芬海洋生物科技有限公司 | 一种含海洋生物成分的口腔溃疡用软膏 |
Non-Patent Citations (1)
Title |
---|
M. J. A. ARMELIN,ET AL.: "Effect of chelated mineral supplementation on the absorption of Cu, Fe, K, Mn and Zn in horse hair", 《JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109010364A (zh) * | 2018-09-12 | 2018-12-18 | 仲恺农业工程学院 | 一种包衣结构的甘氨酸亚铁肠溶型缓释微丸及制备方法 |
CN109043221A (zh) * | 2018-09-25 | 2018-12-21 | 建德市维丰饲料有限公司 | 一种用于家禽的饲料预混料的制备方法及其产品和应用 |
CN112675160A (zh) * | 2020-12-31 | 2021-04-20 | 河北力维素科技有限公司 | 一种氨基酸矿物盐微量元素组合物及其制备方法 |
CN113317428A (zh) * | 2021-06-16 | 2021-08-31 | 海而思(郑州)科技有限公司 | 一种钙铁锌固体制剂及其制备方法 |
CN113317428B (zh) * | 2021-06-16 | 2022-08-09 | 海而思(郑州)科技有限公司 | 一种钙铁锌固体制剂及其制备方法 |
RU2817424C1 (ru) * | 2023-08-23 | 2024-04-16 | Федеральное Государственное бюджетное научное учреждение "Федеральный научный центр биологических систем и агротехнологий российской академии наук" | Способ повышения содержания макро- и эссенциальных элементов в мясе бройлеров |
Also Published As
Publication number | Publication date |
---|---|
CN105687204B (zh) | 2018-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101912049A (zh) | 包被微量元素预混料及其制备方法 | |
CN105687204A (zh) | 一种甘氨酸金属螯合物复合物及其制备方法 | |
CN101744120B (zh) | 乳仔猪微量元素预混料 | |
CN102550836B (zh) | 动物营养添加剂微量元素复合包及其制备方法和应用 | |
CN102524540B (zh) | 节约型微量元素复合包及其制备方法和应用 | |
CN102125179B (zh) | 适用于乳仔猪的软胶囊营养补剂及其制备方法 | |
JP2008525442A (ja) | 鉄を含む組成物 | |
ZA200504457B (en) | Dimetalhydroxy malates | |
CN104770597A (zh) | 用于羔羊育肥的矿物质、维生素添加剂 | |
WO2010074602A1 (ru) | Биодоступная форма микроэлементных добавок в кормовые смеси для животных и птиц | |
CN102578386B (zh) | 复合甘氨酸多矿及其制备方法和应用 | |
CN106243176A (zh) | 蔗糖铜络合物的制备方法 | |
CN101472488A (zh) | 具有改进溶解度的混合氨基酸/无机物化合物 | |
CN107232414A (zh) | 一种乳仔猪饲料的复合添加剂和制备方法 | |
UA16639U (en) | Method of metabolism correction, pig productivity increasing and production quality improvement | |
CN111094301B (zh) | 甲硫氨酸-金属螯合物及其制备方法 | |
RU2755307C2 (ru) | Хелатный комплекс метионина с металлом и способ его получения | |
US20050019390A1 (en) | Dosage system and dosage vehicle therefor | |
MXPA05002523A (es) | Uso de quelatos metalicos en la alimentacion humana o animal. | |
CN105813470A (zh) | 递送高度可吸收的金属的乙二胺金属络合物用于动物营养的用途 | |
AU2002332990B2 (en) | Dosage system & dosage vehicle therefor | |
FI56613C (fi) | Preparat foer tillsats i djurfoder | |
RU2530996C2 (ru) | Способ обогащения кормовых рационов овец | |
CN106578557A (zh) | 复合微量元素添加剂及其应用和猪用饲料 | |
RU2275051C2 (ru) | Углеводно-минеральная добавка "фелуцен" для сельскохозяйственных животных |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |